CellSeed Inc. (7776.T)
JPY 408.0
(-7.69%)
JPY 408.0
(-7.69%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.01 Billion JPY | -120.27% |
| 2022 | -913.46 Million JPY | -33.03% |
| 2021 | -686.67 Million JPY | 47.21% |
| 2020 | -1.3 Billion JPY | -22.15% |
| 2019 | -1.06 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -2.02 Billion JPY | -4.52% |
| 2024 Q1 | -1.93 Billion JPY | 3.62% |
| 2023 Q2 | -1.43 Billion JPY | -2.64% |
| 2023 Q4 | -2.01 Billion JPY | 1.7% |
| 2023 Q1 | -1.39 Billion JPY | -53.06% |
| 2023 FY | -2.01 Billion JPY | -120.27% |
| 2023 Q3 | -2.04 Billion JPY | -42.64% |
| 2022 Q3 | -780.77 Million JPY | 0.0% |
| 2022 FY | -913.46 Million JPY | -33.03% |
| 2022 Q4 | -913.46 Million JPY | -16.99% |
| 2021 FY | -686.67 Million JPY | 47.21% |
| 2020 FY | -1.3 Billion JPY | -22.15% |
| 2019 FY | - JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 370.888% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -77.438% |
| GNI Group Ltd. | -17.93 Billion JPY | 88.781% |
| Linical Co., Ltd. | -4.46 Billion JPY | 54.92% |
| Trans Genic Inc. | -221.16 Million JPY | -809.731% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 54.21% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 57.995% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 240.355% |
| AnGes, Inc. | -3.79 Billion JPY | 47.02% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -378.139% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 108.078% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -303.9% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -331.447% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 25.649% |
| CanBas Co., Ltd. | -1.88 Billion JPY | -6.559% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -104.863% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 40.77% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -94.484% |
| Kidswell Bio Corporation | 343.58 Million JPY | 685.596% |
| PeptiDream Inc. | 3.29 Billion JPY | 161.119% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -106.874% |
| Ribomic Inc. | -2.09 Billion JPY | 4.177% |
| SanBio Company Limited | -3.78 Billion JPY | 46.908% |
| Healios K.K. | -2.19 Billion JPY | 8.126% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -112.946% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 23.326% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -41.987% |
| StemRIM | -8.41 Billion JPY | 76.076% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 57.04% |
| FunPep Company Limited | -1.79 Billion JPY | -12.193% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 5.825% |
| Stella Pharma Corporation | -1.11 Billion JPY | -79.742% |
| TMS Co., Ltd. | -3.44 Billion JPY | 41.623% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 63.784% |
| Cuorips Inc. | -5.56 Billion JPY | 63.819% |
| K Pharma,Inc. | -3.26 Billion JPY | 38.402% |
| Takara Bio Inc. | -32.2 Billion JPY | 93.752% |
| ReproCELL Incorporated | -2.93 Billion JPY | 31.541% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -204.412% |
| StemCell Institute Inc. | -2.83 Billion JPY | 29.072% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 2.628% |